Passion for cancer research and clinical oncology. Radiation Oncology at MSKCC. #CancerOutcomes #NeuroOnc #CancerMetabolism
Joined April 2020
- Tweets1.1K
- Following547
- Followers474
- Likes4.9K
Pinned Tweet
Very proud and fortunate to be mentored by Dr. Neugut, who won the @columbiacancer Mentor of the Year Award
Connor Kinslow, MD retweeted
As treatment options continue to evolve, keeping prognostic tools up to date is essential for guiding treatment for patients with brain metastases. Grateful to be part of this incredible team!
#BrainMetastases #Radonc #GPA #prognosis @OhioStateRadOnc
sciencedirect.com/science/ar…
Pleasure to have a colleague notify me today that our article is in print in the @JCO_ASCO
"Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas"
ascopubs.org/doi/full/10.120…
1/n Virtually every RCT of CRT for LGG used age ≥40 yrs as inclusion. Every major guidelines still cites age as a high-risk factor for LGG
Connor Kinslow, MD retweeted
1/6:
I am excited to share our multi-institutional F-SHARP phase I/II trial, now published in @JCO_ASCO!
doi.org/10.1200/JCO-25-02730
There are limited prospective data defining the optimal management of intraprostatic radiorecurrence (IPR) after definitive RT for prostate cancer.
We asked:
1. Is dose-escalated focal salvage high dose rate brachytherapy safe and effective for IPR?
2. Can Decipher (@Veracyte) identify patients with higher risk of recurrence with salvage ReRT that may benefit from therapeutic intensification?
🧵👇
Connor Kinslow, MD retweeted
Fantastic work led by @dtbergman analyzing 3,893 patients treated with Linac SRS for brain mets. OS plateaus from 5-20 lesions & salvage WBRT is rare. Data support an SRS-first strategy over fixed lesion limits! doi.org/10.1093/noajnl/vdag2… @MSKCancerCenter @MSK_RadOnc
Connor Kinslow, MD retweeted
Excited to share our new paper out today in @NatureMetabolism! "Hyperglycosylation is a metabolic driver of Alzheimer’s disease"
*We bridged spatial metabolomics (MALDI-MSI glycomics + lipidomics + isotopic pulse-chase tracing) directly to experimental biochemistry (genetic knockdown of glycan enzymes + glucosamine supplementation in AD models) and real-world public health data (EHR analysis showing glucosamine use linked to faster MCI-to-AD progression and worse survival).
**Key takeaway: The AD brain shows conserved hyperglycosylation driven by ramped-up glycan biosynthesis — not just a byproduct, but a causal driver. Reducing it helps cognition; boosting it (e.g., via glucosamine) worsens outcomes.
***We applied cutting-edge spatial tech to functional validation and clinical translation.
Full open-access paper: nature.com/articles/s42255-0…
Huge thanks to the incredible team, collaborators (incl. Matt Gentry, Stefan Prokop, @ji0ngbi0n , Yi Guo, @lichenbiostat, Ralph Deberardinis & others), and the patients/families who make this work possible.
Connor Kinslow, MD retweeted
Excited to share our new paper with @Mitch_P and @Luke_Pike_MD @pike_lab!
Nearly 4,000 brain mets patients treated with linac-based SRS at MSK: contemporary survival outcomes, prognostic factors, and what happens next with salvage treatment. 🧵
doi.org/10.1093/noajnl/vdag2…
Connor Kinslow, MD retweeted
Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial
thelancet.com/journals/lanep…
To those at @EANOassociation #EANO2026 please consider coming to my presentation at the high-impact selected abstracts session at 9a:
“Ki-67 proliferation index and prognosis in 1p19q-code letter oligodendrogliomas: analysis of two large US cohorts”
Connor Kinslow, MD retweeted
We have waited more than a decade for this: ROAM is presented in Rome #EANO2026! See the results of ROAM/EORTC-1308, now also published in @TheLancet!
@EANOassociation
thelancet.com/journals/lance…
